Its possible application in the management of large-bowel cancer

Giora M. Mavligit, Jordan U. Gutterman, Michael A. Burgess, John F. Speer, Richard C. Reed, Richard C. Martin, Charles M. McBride, Edward M. Copeland, Edmund A. Gehan, Evan M Hersh

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The rapidly emerging therapeutic modality of cancer immunotherapy has been applied to a carefully selected group of patients with carcinoma of the large bowel. Patient selection was based on the extent of disease at the time of definitive surgery, and the strict provision that all discernible disease was removed. Thus, 20 consecutive patients who had mesenteric lymph node involvement were subsequently allocated to receive either BCG alone or the combination of 5-FU plus BCG as adjuvant treatment to surgery. After 10 months of patient accrual, all patients were clinically free of disease. Therapy was well tolerated without significant morbidity. Although general immunocompetence of these patients has improved on treatment, it is still too early to say whether immunotherapy will be clinically beneficial. Serial determination of plasma levels of CEA was useful in ruling out suspected recurrent disease. In contrast, preoperative plasma levels of CEA in patients with Dukes' C classification were elevated in only 40%. This indicates that its value in establishing the primary diagnosis is still doubtful.

Original languageEnglish (US)
Pages (from-to)1047-1053
Number of pages7
JournalThe American Journal of Digestive Diseases
Volume19
Issue number11
DOIs
StatePublished - Nov 1974
Externally publishedYes

Fingerprint

Colonic Neoplasms
Mycobacterium bovis
Immunotherapy
Immunocompetence
Therapeutics
Fluorouracil
Patient Selection
Lymph Nodes
Morbidity
Carcinoma
Neoplasms

ASJC Scopus subject areas

  • Gastroenterology
  • Medicine(all)

Cite this

Mavligit, G. M., Gutterman, J. U., Burgess, M. A., Speer, J. F., Reed, R. C., Martin, R. C., ... Hersh, E. M. (1974). Its possible application in the management of large-bowel cancer. The American Journal of Digestive Diseases, 19(11), 1047-1053. https://doi.org/10.1007/BF01255789

Its possible application in the management of large-bowel cancer. / Mavligit, Giora M.; Gutterman, Jordan U.; Burgess, Michael A.; Speer, John F.; Reed, Richard C.; Martin, Richard C.; McBride, Charles M.; Copeland, Edward M.; Gehan, Edmund A.; Hersh, Evan M.

In: The American Journal of Digestive Diseases, Vol. 19, No. 11, 11.1974, p. 1047-1053.

Research output: Contribution to journalArticle

Mavligit, GM, Gutterman, JU, Burgess, MA, Speer, JF, Reed, RC, Martin, RC, McBride, CM, Copeland, EM, Gehan, EA & Hersh, EM 1974, 'Its possible application in the management of large-bowel cancer', The American Journal of Digestive Diseases, vol. 19, no. 11, pp. 1047-1053. https://doi.org/10.1007/BF01255789
Mavligit GM, Gutterman JU, Burgess MA, Speer JF, Reed RC, Martin RC et al. Its possible application in the management of large-bowel cancer. The American Journal of Digestive Diseases. 1974 Nov;19(11):1047-1053. https://doi.org/10.1007/BF01255789
Mavligit, Giora M. ; Gutterman, Jordan U. ; Burgess, Michael A. ; Speer, John F. ; Reed, Richard C. ; Martin, Richard C. ; McBride, Charles M. ; Copeland, Edward M. ; Gehan, Edmund A. ; Hersh, Evan M. / Its possible application in the management of large-bowel cancer. In: The American Journal of Digestive Diseases. 1974 ; Vol. 19, No. 11. pp. 1047-1053.
@article{b3304e238b364dcf85899e2c2d929eb7,
title = "Its possible application in the management of large-bowel cancer",
abstract = "The rapidly emerging therapeutic modality of cancer immunotherapy has been applied to a carefully selected group of patients with carcinoma of the large bowel. Patient selection was based on the extent of disease at the time of definitive surgery, and the strict provision that all discernible disease was removed. Thus, 20 consecutive patients who had mesenteric lymph node involvement were subsequently allocated to receive either BCG alone or the combination of 5-FU plus BCG as adjuvant treatment to surgery. After 10 months of patient accrual, all patients were clinically free of disease. Therapy was well tolerated without significant morbidity. Although general immunocompetence of these patients has improved on treatment, it is still too early to say whether immunotherapy will be clinically beneficial. Serial determination of plasma levels of CEA was useful in ruling out suspected recurrent disease. In contrast, preoperative plasma levels of CEA in patients with Dukes' C classification were elevated in only 40{\%}. This indicates that its value in establishing the primary diagnosis is still doubtful.",
author = "Mavligit, {Giora M.} and Gutterman, {Jordan U.} and Burgess, {Michael A.} and Speer, {John F.} and Reed, {Richard C.} and Martin, {Richard C.} and McBride, {Charles M.} and Copeland, {Edward M.} and Gehan, {Edmund A.} and Hersh, {Evan M}",
year = "1974",
month = "11",
doi = "10.1007/BF01255789",
language = "English (US)",
volume = "19",
pages = "1047--1053",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Plenum Publishers",
number = "11",

}

TY - JOUR

T1 - Its possible application in the management of large-bowel cancer

AU - Mavligit, Giora M.

AU - Gutterman, Jordan U.

AU - Burgess, Michael A.

AU - Speer, John F.

AU - Reed, Richard C.

AU - Martin, Richard C.

AU - McBride, Charles M.

AU - Copeland, Edward M.

AU - Gehan, Edmund A.

AU - Hersh, Evan M

PY - 1974/11

Y1 - 1974/11

N2 - The rapidly emerging therapeutic modality of cancer immunotherapy has been applied to a carefully selected group of patients with carcinoma of the large bowel. Patient selection was based on the extent of disease at the time of definitive surgery, and the strict provision that all discernible disease was removed. Thus, 20 consecutive patients who had mesenteric lymph node involvement were subsequently allocated to receive either BCG alone or the combination of 5-FU plus BCG as adjuvant treatment to surgery. After 10 months of patient accrual, all patients were clinically free of disease. Therapy was well tolerated without significant morbidity. Although general immunocompetence of these patients has improved on treatment, it is still too early to say whether immunotherapy will be clinically beneficial. Serial determination of plasma levels of CEA was useful in ruling out suspected recurrent disease. In contrast, preoperative plasma levels of CEA in patients with Dukes' C classification were elevated in only 40%. This indicates that its value in establishing the primary diagnosis is still doubtful.

AB - The rapidly emerging therapeutic modality of cancer immunotherapy has been applied to a carefully selected group of patients with carcinoma of the large bowel. Patient selection was based on the extent of disease at the time of definitive surgery, and the strict provision that all discernible disease was removed. Thus, 20 consecutive patients who had mesenteric lymph node involvement were subsequently allocated to receive either BCG alone or the combination of 5-FU plus BCG as adjuvant treatment to surgery. After 10 months of patient accrual, all patients were clinically free of disease. Therapy was well tolerated without significant morbidity. Although general immunocompetence of these patients has improved on treatment, it is still too early to say whether immunotherapy will be clinically beneficial. Serial determination of plasma levels of CEA was useful in ruling out suspected recurrent disease. In contrast, preoperative plasma levels of CEA in patients with Dukes' C classification were elevated in only 40%. This indicates that its value in establishing the primary diagnosis is still doubtful.

UR - http://www.scopus.com/inward/record.url?scp=0016262781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016262781&partnerID=8YFLogxK

U2 - 10.1007/BF01255789

DO - 10.1007/BF01255789

M3 - Article

C2 - 4422564

AN - SCOPUS:0016262781

VL - 19

SP - 1047

EP - 1053

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 11

ER -